Latest From Genfit SA
Intercept hopes to be first to market in NASH with an indication to treat fibrosis. It also is enrolling a study to show a benefit in NASH patients with cirrhosis.
Recently filed NDA for obeticholic acid relies on US FDA's specified endpoints for treatment of fibrosis, but European standards are less clear cut, the company acknowledges.
Co-founder and CEO Mouney will turn over the reins to former GSK and Lilly exec Pascal Prigent in mid-September.
The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- Western Europe
- Parent & Subsidiaries
- Genfit SA
- Senior Management
Jean-Francois Mouney, Chmn. & CEO
Nathalie Huitorel, EVP, CFO & Chief Administrative Officer
Dean Hum, PhD, COO
Carol L Addy, MD, CMO
- Contact Info
Phone: (33) 3 20 16 40 00
885 Ave. Eugene Avinee
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.